Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.
AuthorWitkiewicz, Agnieszka K
Mills, Gordon B
O'Reilly, Eileen M
Knudsen, Erik S
AffiliationUniv Arizona, Dept Pathol
Univ Arizona, Ctr Canc
Univ Arizona, Dept Med
MetadataShow full item record
CitationIntegrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. 2016, 16 (7):2017-31 Cell Rep
Rights© 2016 The Author(s). Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0).
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractPancreatic ductal adenocarcinoma (PDAC) harbors the worst prognosis of any common solid tumor, and multiple failed clinical trials indicate therapeutic recalcitrance. Here, we use exome sequencing of patient tumors and find multiple conserved genetic alterations. However, the majority of tumors exhibit no clearly defined therapeutic target. High-throughput drug screens using patient-derived cell lines found rare examples of sensitivity to monotherapy, with most models requiring combination therapy. Using PDX models, we confirmed the effectiveness and selectivity of the identified treatment responses. Out of more than 500 single and combination drug regimens tested, no single treatment was effective for the majority of PDAC tumors, and each case had unique sensitivity profiles that could not be predicted using genetic analyses. These data indicate a shortcoming of reliance on genetic analysis to predict efficacy of currently available agents against PDAC and suggest that sensitivity profiling of patient-derived models could inform personalized therapy design for PDAC.
VersionFinal published version
SponsorsCancer Center Support grant of the Simmons Cancer Center [P30 CA142543]; NIH [CA142543-05S2]
Except where otherwise noted, this item's license is described as © 2016 The Author(s). Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0).
- A pharmacogenomic analysis using L1000CDS<sup>2</sup> identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells.
- Authors: Choi EA, Choi YS, Lee EJ, Singh SR, Kim SC, Chang S
- Issue date: 2019 Nov 28
- Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility.
- Authors: Knudsen ES, Balaji U, Mannakee B, Vail P, Eslinger C, Moxom C, Mansour J, Witkiewicz AK
- Issue date: 2018 Mar
- Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
- Authors: Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB
- Issue date: 2015 Dec
- Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
- Authors: Wang X, Xie J, Lu X, Li H, Wen C, Huo Z, Xie J, Shi M, Tang X, Chen H, Peng C, Fang Y, Deng X, Shen B
- Issue date: 2017 Jul 28
- Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
- Authors: Zhao X, Fan W, Xu Z, Chen H, He Y, Yang G, Yang G, Hu H, Tang S, Wang P, Zhang Z, Xu P, Yu M
- Issue date: 2016 Dec 6